SEC 13F Intelligence

Managers / Q1 2022 · view latest →

Consonance Capital Management LP

CIK 0001544773 · 1370 AVENUE OF THE AMERICAS, SUITE 3301, NEW YORK, NY, 10019 · 212.660-8062

Reported Value
$59M
Q1 2022
Positions
8
Filings on Record
15
2019–present window
Filed
May 16, 2022
original filing

Summary

Consonance Capital Management LP reported $59M in U.S.-listed holdings across 8 positions for Q1 2022.

The portfolio is heavily concentrated: TNDM alone accounts for 29.1% of reported value.

Compared with Q4 2021, the fund opened 0 new positions and exited 7.

Portfolio Metrics

Turnover
+0.0%
vs prior filed quarter
Largest Position
+29.1%
Tandem Diabetes Care

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q1 ’19: $1.6BQ1 ’19Q2 ’19: $1.4BQ3 ’19: $1.0BQ3 ’19Q4 ’19: $1.6BQ1 ’20: $1.3BQ1 ’20Q2 ’20: $1.7BQ3 ’20: $821MQ3 ’20Q4 ’20: $1.1BQ1 ’21: $938MQ1 ’21Q2 ’21: $831MQ3 ’21: $183MQ3 ’21Q4 ’21: $153MQ1 ’22: $59MQ1 ’22Q2 ’22: $24MQ3 ’22: $7MQ3 ’22filingsflow.com

Portfolio Composition

By security type
Common Stock: 58.0%ADR: 21.1%Other: 20.4%Equity WRT: 0.5%
  • Common Stock · 58.0% · $34M
  • ADR · 21.1% · $12M
  • Other · 20.4% · $12M
  • Equity WRT · 0.5% · $291,000

Quarter-over-Quarter Changes full breakdown →

vs Q4 2021 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
RESEARCH ALLIANCE CORP IISOLD OUT−300.0K0−$3M$0
JIYA ACQUISITION CORPSOLD OUT−300.0K0−$3M$0
MEDICUS SCIENCES ACQUISITIONSOLD OUT−300.0K0−$3M$0
ARYA SCIENCES ACQUISITN CORPSOLD OUT−300.0K0−$3M$0
PANACEA ACQUISITION CORP IISOLD OUT−200.0K0−$2M$0
CAREMAX INCSOLD OUT−46.0K0−$64,000$0
MEDICUS SCIENCES ACQUISITIONSOLD OUT−33.3K0−$24,000$0
GMEDGLOBUS MED INCTRIMMED−266.2K107.0K−$19M$8M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2022

7 positions (from 8 filing rows — )
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1TNDMTANDEM DIABETES CARE INChistory →COM NEW29.07%$17M147.3K
2SLNSILENCE THERAPEUTICS PLChistory →ADS21.08%$12M654.1K
3SRZNWSURROZEN INCCOM · *W EXP 08/01/20318.35%$11M4.66M
4GMEDGLOBUS MED INChistory →CL A13.40%$8M107.0K
5CMPXCOMPASS THERAPEUTICS INChistory →COM8.05%$5M3.50M
6UTHRUNITED THERAPEUTICS CORP DELhistory →COM7.48%$4M24.6K
7HELIX ACQUISITION CORPCOM CL A2.58%$2M137.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2022$7M2Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$24M7Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$59M8May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$153M15Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$183M17Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$831M32Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$938M35May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$1.1B38Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$821M27Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.7B32Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$1.3B31May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$1.6B35Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$1.0B30Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$1.4B30Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$1.6B26May 15, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.